Ares Management (ARES) FY2025 10-K Annual Report

Filed: Feb 12, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR

Ares Management (ARES) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Ares Management FY2025 10-K Analysis

Business Overview

  • Core business model not detailed; filing references Zoetis corporate governance and proxy statements extensively
  • No new products, services, or segments introduced or emphasized in 2026 filing text
+3 more insights

Management Discussion & Analysis

  • Revenue $9,467M for 2025, up 2% YoY from $9,256M in 2024
  • Net income $2,673M, increased 8% from $2,486M in 2024; adjusted net income $2,847M, up 6% YoY
+3 more insights

Risk Factors

  • Cybersecurity risk with potential uninsured costs despite cybersecurity insurance coverage
  • Dependency on third-party cloud infrastructure for critical information systems operations
+3 more insights

Ares Management FY2025 Key Financial Metrics
XBRL

Revenue

$9.5B

+2.3% YoY

Net Income

$2.7B

+7.5% YoY

Net Margin

28.2%

+138bp YoY

ROE

80.2%

+2813bp YoY

Total Assets

$15.5B

+8.6% YoY

EPS (Diluted)

$6.02

+10.1% YoY

Operating Cash Flow

$2.9B

-1.7% YoY

Source: XBRL data from Ares Management FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Ares Management

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.